{"id":668262,"date":"2023-09-18T10:58:01","date_gmt":"2023-09-18T10:58:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=668262"},"modified":"2023-09-18T10:58:01","modified_gmt":"2023-09-18T10:58:01","slug":"hyperkalemia-market-analysis-of-epidemiology-pipeline-products-and-key-pharma-companies-working-in-the-market-companiesardelyx-astrazeneca-vifor-pharma","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/hyperkalemia-market-analysis-of-epidemiology-pipeline-products-and-key-pharma-companies-working-in-the-market-companiesardelyx-astrazeneca-vifor-pharma_668262.html","title":{"rendered":"Hyperkalemia Market: Analysis of Epidemiology, Pipeline Products, and Key Pharma Companies Working in the Market | Companies-Ardelyx, AstraZeneca, Vifor Pharma"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/uploads\/1694753925.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Hyperkalemia Market: Analysis of Epidemiology, Pipeline Products, and Key Pharma Companies Working in the Market | Companies-Ardelyx, AstraZeneca, Vifor Pharma\" src=\"https:\/\/www.abnewswire.com\/uploads\/1694753925.jpeg\" alt=\"Hyperkalemia Market: Analysis of Epidemiology, Pipeline Products, and Key Pharma Companies Working in the Market | Companies-Ardelyx, AstraZeneca, Vifor Pharma\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>Hyperkalemia Market<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">DelveInsight&#8217;s &#8220;Hyperkalemia Market Insights, Epidemiology, and Market Forecast-2032&#8221; report delivers an in-depth understanding of the Hyperkalemia, historical and forecasted epidemiology as well as the Hyperkalemia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/div>\n<p style=\"text-align: justify;\">DelveInsight has launched a new report on&nbsp;<strong>&#8220;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/hyperkalemia-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\">Hyperkalemia &#8211; Market Insights, Epidemiology, and Market Forecast-2032<\/a>&rdquo;.<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Some of the key facts of the&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/hyperkalemia-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\">Hyperkalemia Market Report:<\/a><\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>In 2020, the diagnosed prevalent population of Hyperkalemia in Japan was found to be 503,103, which might increase during the study period of 2019&ndash;2032.<\/li>\n<li>As per the analysis, males contributed to 55% of the total Hyperkalemia patient population in Japan in 2020. As per DelveInsight&rsquo;s analysis, in Japan, there were 276,707 males and 226,397 females with hyperkalemia in 2020.<\/li>\n<li>In Japan, the maximum number of Hyperkalemia patients fall in the age group of 65&ndash;79 years, which will contribute 41.66% in 2020. The lowest proportion of the population was contributed by the age group of 18&ndash;64 years.<\/li>\n<li>As per DelveInsight&rsquo;s analysis, mild cases contributed to 72.5% of the total population in 2020 as compared to moderate and severe cases. While moderate and severe cases only contributed to 19.6% and 7.8%, respectively.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Key benefits of the report:<\/strong><\/p>\n<ol style=\"text-align: justify;\" start=\"1\">\n<li>The hyperkalemia market report covers a descriptive overview and comprehensive insight of the Hyperkalemia Epidemiology and Hyperkalemia&nbsp; market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) &amp; Japan.)<\/li>\n<li>The Hyperkalemia market report provides insights into the current and emerging therapies.<\/li>\n<li>Hyperkalemia market report provides a global historical and forecasted market covering drug outreach in 7MM.<\/li>\n<li>The Hyperkalemia market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Hyperkalemia market.<\/li>\n<\/ol>\n<p style=\"text-align: justify;\"><strong>Hyperkalemia Overview<\/strong><\/p>\n<p style=\"text-align: justify;\">Hyperkalemia is defined as the high potassium level in the blood. Potassium helps in the proper functioning of nerves and muscles, including the heart, but too much potassium in the blood can be dangerous and can cause serious heart problems and sudden death.&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Hyperkalemia Market&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\">The dynamics of the&nbsp;<strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/hyperkalemia-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\">Hyperkalemia market<\/a><\/strong>&nbsp;are anticipated to change in the coming years owing to the expected launch of emerging therapies by companies such as <strong>Ardelyx, AstraZeneca, Vifor Pharma<\/strong>, and others during the study period 2019-2032.<\/p>\n<p style=\"text-align: justify;\"><strong>Learn more by requesting for sample @&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/hyperkalemia-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\">Hyperkalemia Market Landscape<\/a>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Hyperkalemia Pipeline Therapies and Key Companies&nbsp;<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>RDX013: Ardelyx<\/li>\n<li>Lokelma: AstraZeneca<\/li>\n<li>Veltassa: Vifor Pharma<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Table of Contents<\/strong><\/p>\n<p style=\"text-align: justify;\">1. Report Introduction<\/p>\n<p style=\"text-align: justify;\">2. Executive Summary<\/p>\n<p style=\"text-align: justify;\">3. SWOT analysis<\/p>\n<p style=\"text-align: justify;\">4. Hyperkalemia Patient Share (%) Overview at a Glance<\/p>\n<p style=\"text-align: justify;\">5. Hyperkalemia Market Overview at a Glance<\/p>\n<p style=\"text-align: justify;\">6. Hyperkalemia Disease Background and Overview<\/p>\n<p style=\"text-align: justify;\">7. Hyperkalemia Epidemiology and Patient Population<\/p>\n<p style=\"text-align: justify;\">8. Country-Specific Patient Population of Hyperkalemia&nbsp;<\/p>\n<p style=\"text-align: justify;\">9. Hyperkalemia Current Treatment and Medical Practices<\/p>\n<p style=\"text-align: justify;\">10. Unmet Needs<\/p>\n<p style=\"text-align: justify;\">11. Hyperkalemia Emerging Therapies<\/p>\n<p style=\"text-align: justify;\">12. Hyperkalemia Market Outlook<\/p>\n<p style=\"text-align: justify;\">13. Country-Wise Hyperkalemia Market Analysis (2019-2032)<\/p>\n<p style=\"text-align: justify;\">14. Market Access and Reimbursement of Therapies<\/p>\n<p style=\"text-align: justify;\">15. Market drivers<\/p>\n<p style=\"text-align: justify;\">16. Market barriers<\/p>\n<p style=\"text-align: justify;\">17. Appendix<\/p>\n<p style=\"text-align: justify;\">18. Hyperkalemia Report Methodology<\/p>\n<p style=\"text-align: justify;\">19. DelveInsight Capabilities<\/p>\n<p style=\"text-align: justify;\">20. Disclaimer<\/p>\n<p style=\"text-align: justify;\">21. About DelveInsight<\/p>\n<p style=\"text-align: justify;\"><strong>Click here to read more about&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/hyperkalemia-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\" target=\"_blank\">Hyperkalemia Market Outlook 2032<\/a>.<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Related Reports:<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Hyperkalemia Pipeline&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Hyperkalemia Epidemiolog<\/strong><\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Kritika Rehani<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=hyperkalemia-market-analysis-of-epidemiology-pipeline-products-and-key-pharma-companies-working-in-the-market-companiesardelyx-astrazeneca-vifor-pharma\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +91-9650213330<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> Nevada<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=hyperkalemia-market-analysis-of-epidemiology-pipeline-products-and-key-pharma-companies-working-in-the-market-companiesardelyx-astrazeneca-vifor-pharma\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Hyperkalemia Market DelveInsight&#8217;s &#8220;Hyperkalemia Market Insights, Epidemiology, and Market Forecast-2032&#8221; report delivers an in-depth understanding of the Hyperkalemia, historical and forecasted epidemiology as well as the Hyperkalemia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/hyperkalemia-market-analysis-of-epidemiology-pipeline-products-and-key-pharma-companies-working-in-the-market-companiesardelyx-astrazeneca-vifor-pharma_668262.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,435,405,406,404],"tags":[],"class_list":["post-668262","post","type-post","status-publish","format-standard","hentry","category-Business","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/668262","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=668262"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/668262\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=668262"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=668262"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=668262"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}